Evidence map›Paper›PMID 27926486›Full record

ArticleOncotarget2017

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.

Elizabeth M Perez, Joslyn Foley, Timelia Tison, Rute Silva, Javier Gordon Ogembo

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Overview of virus and cancer relationships. Position paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Elizabeth M PerezDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Joslyn FoleyDepartment of Experimental Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Timelia TisonDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Rute SilvaDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Javier Gordon OgemboDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
University of Massachusetts Chan Medical School · USBeckman Research InstituteCity of Hope · US

Funding

Unmasking the roles of KSHV glycoproteins in virus entry and vaccine developmentK01CA184388 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI OGEMBO, JAVIER GORDON · 2014 to 2018
$536k
NCI NIH HHS K01 CA184388
6 · The paper itself

Abstract

Previous Epstein-Barr virus (EBV) prophylactic vaccines based on the major surface glycoprotein gp350/220 as an immunogen have failed to block viral infection in humans, suggesting a need to target other viral envelope glycoproteins. In this study, we reasoned that incorporating gH/gL or gB, critical glycoproteins for viral fusion and entry, on the surface of a virus-like particle (VLP) would be more immunogenic than gp350/220 for generating effective neutralizing antibodies to prevent viral infection of both epithelial and B cell lines. To boost the humoral response and trigger cell-mediated immunity, EBV nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2), intracellular latency proteins expressed in all EBV-infected cells, were also included as critical components of the polyvalent EBV VLP. gH/gL-EBNA1 and gB-LMP2 VLPs were efficiently produced in Chinese hamster ovary cells, an FDA-approved vehicle for mass-production of biologics. Immunization with gH/gL-EBNA1 and gB-LMP2 VLPs without adjuvant generated both high neutralizing antibody titers in vitro and EBV-specific T-cell responses in BALB/c mice. These data demonstrate that will be invaluable not only in preventing EBV infection, but importantly, in preventing and treating the 200,000 cases of EBV-associated cancers that occur globally every year.

Indexed as

AnimalsAntibodies, NeutralizingCHO CellsCricetinaeCricetulusEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensFemaleHerpesvirus 4, HumanHumansImmunity, CellularImmunizationMiceMice, Inbred BALB CStomach NeoplasmsT-LymphocytesAntibodies, NeutralizingEBV-associated membrane antigen, Epstein-Barr virusEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensViral Matrix ProteinsEpstein-Barr virusvaccineviral glycoproteinsviral latency proteinsvirus-like particles

Identifiers

PMID27926486
PMCPMC5386682
OpenAlexW2559162730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.